Bioprocessing Cell Lines

A cell line that maintains favorable growth and productivity characteristics is vital for biopharmaceutical manufacturing processes, whether you are producing monoclonal antibodies, recombinant proteins, or viral vectors for gene therapies. Our ready-to-use cell line systems can accelerate your upstream development by greatly reducing the time, cost, and risk of developing new cell lines. Our cell lines are rationally engineered and designed for compliant biomanufacturing.   

Key features include:

• Fully traceable cell lines with comprehensive documentation
• cGMP banked and characterized
• Paired, optimized, and chemically defined media and feeds
• Comprehensive user protocols for efficient cell line development and seamless scale-up, supported by technical consultation

Sf-RVN^® Platform For Improving the Safety Profile of Your Bioprocesses

The majority of Spodoptera frugiperda cells (such as Sf9) contain a rhabdovirus that is considered a process contaminant and must be eliminated during the bioprocess.

Our Sf-RVN^® Platform offers a rhabdovirus-free alternative for bioprocesses and enhances risk mitigation.

The Sf-RVN^® Platform is a synergy between a Sf9 rhabdovirus-negative cell line with companion chemically defined medium, specifically formulated to get excellent growth and productivity of the cell line.

Combined, the Sf-RVN^® Insect Cell Line with companion EX-CELL^® CD Insect Cell Medium provide a high performant platform optimal to produce recombinant proteins, viral vaccines such as viral like particles (VLP) and adeno-associated vectors (AAV) for gene therapy applications.

For more information on the Sf-RVN^® Insect Cell Line or to order, please click here.

CHOZN^® Platform for Production of Biologics and Recombinant Proteins

Our CHOZN^® platform is a Chinese Hamster Ovary (CHO) mammalian cell expression system that allows for faster, simpler selection and scale-up of high-producing clones for production of biologics and therapeutic recombinant proteins. It includes:

• High-performing CHO cell lines
• Paired media and feeds
• Optimized expression vectors
• Robust protocols

VirusExpress^® Lentiviral Production Platform

Our VirusExpress^® platform offers a transfection-based solution for lentiviral (LV) production challenges, featuring a suspension adapted cell line, chemically defined medium, and process with proven performance at clinically relevant scale. The platform can dramatically reduce time in process development and scale-up, either within your own facilities or using our contract manufacturing capabilities to speed your therapy to patients. Attributes include:

• cGMP banked and characterized cells
• Chemically defined medium
• Proven performance for cell growth, plasmid transfection, and lentiviral production in bioreactors at scale
• License available for clinical and commercial use

VirusExpress^® 293T Lentiviral Production Cells are optimized for production of lentiviral vectors for gene therapy applications. Comprehensive user protocols guide you from seed train through at-scale transfection and virus production, allowing seamless scale-up. Robust quality documentation enables regulatory filings and commercialization of your gene-modified cell therapy.

VirusExpress^® AAV Production Platform

The VirusExpress^® AAV Production Platform offers a transfection based solution to Adeno-Associated Viral (AAV) production challenges, featuring a suspension adapted cell line, chemically defined medium, and a clinically relevant process dramatically reducing time to commercial production. VirusExpress^® offers the flexibility to use either our contract manufacturing capabilities or your own facilities to speed your therapy to patients.

• A suspension adapted cell line of 293 AAV Production Cells optimized for production of AAV vectors for gene therapy applications.
  
• Chemically defined medium to alleviate animal origin and supply chain concerns.
  
• Cell banks manufactured according to GMP (21CFR210, 211, 600, 610) and fully characterized.
  
• Proven performance for cell growth, plasmid transfection, and AAV production in large-scale bioreactors at clinically and commercially relevant scale which yielded genome titers in excess of >2x10¹⁰ gc/mL.
  
• Licenses available for research, clinical and commercial use dependent on which phase of gene therapy development is needed.
• Reduced time in process development and scale-up by approximately 40%.
• Robust quality documentation to support regulatory filings and commercialization of your gene modified cell therapy or gene therapy.

We have the right cell lines, media products, manufacturing technologies and expertise to meet our customers’ timelines and their patients’ needs. By utilizing the VirusExpress^® AAV Production Platform, we estimate you may be able to begin clinical manufacture in as little as 6 months as opposed to ~3 years for a custom cell line and process since clone selection, cell line development and GMP cell banking are complete, as well as substantial process development and largescale bioreactor development. Leveraging our expertise in viral vector manufacturing as well as utilizing our templated process solutions will help deliver your gene therapy to patients faster.